Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
Status:
Not yet recruiting
Trial end date:
2028-04-28
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of immunosuppressive therapy
(IST) in participants treated with asfotase alfa who demonstrate immune-mediated loss of
effectiveness (LoE).